Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Assets (2021 - 2025)

Roivant Sciences' Assets history spans 5 years, with the latest figure at $5.2 billion for Q4 2025.

  • For Q4 2025, Assets fell 9.79% year-over-year to $5.2 billion; the TTM value through Dec 2025 reached $5.2 billion, down 9.79%, while the annual FY2025 figure was $5.4 billion, 24.72% down from the prior year.
  • Assets reached $5.2 billion in Q4 2025 per ROIV's latest filing, up from $5.1 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $7.3 billion in Q4 2023 to a low of $2.1 billion in Q3 2023.
  • Average Assets over 5 years is $4.0 billion, with a median of $3.0 billion recorded in 2021.
  • Peak YoY movement for Assets: dropped 28.6% in 2022, then skyrocketed 231.95% in 2023.
  • A 5-year view of Assets shows it stood at $2.8 billion in 2021, then decreased by 21.31% to $2.2 billion in 2022, then surged by 231.95% to $7.3 billion in 2023, then decreased by 20.79% to $5.8 billion in 2024, then decreased by 9.79% to $5.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Assets are $5.2 billion (Q4 2025), $5.1 billion (Q3 2025), and $5.0 billion (Q2 2025).